ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Brain Diseases
Nervous System Diseases
Central Nervous System Diseases

Alzheimer's Disease trials near New Haven, CT, USA:

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo
Drug: CT1812

Phase 2

Cognition Therapeutics
Cognition Therapeutics

New Haven, Connecticut, United States and 50 other locations

reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

Phase 3

Lilly
Lilly

New Haven, Connecticut, United States and 75 other locations

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Active, not recruiting
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Solanezumab
Drug: E2814

Phase 2, Phase 3

The Washington University
The Washington University

New Haven, Connecticut, United States and 37 other locations

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Active, not recruiting
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Lecanemab
Drug: Matching Placebo (E2814)

Phase 2, Phase 3

The Washington University
The Washington University

New Haven, Connecticut, United States and 35 other locations

on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Drug: E2814
Drug: Lecanemab

Phase 2

Eisai
Eisai

New Haven, Connecticut, United States and 25 other locations

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Active, not recruiting
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

New Haven, Connecticut, United States and 109 other locations

and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether admin ...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: ONO-2020

Phase 2

Ono Pharmaceuticals
Ono Pharmaceuticals

Stony Brook, New York, United States and 101 other locations

administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug

Phase 2

Acumen Pharmaceuticals

Norwalk, Connecticut, United States and 72 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab SC
Drug: Lecanemab IV

Phase 3

Eisai
Eisai

New Haven, Connecticut, United States and 246 other locations

The overall objective of this study is to compare the overall pattern of \[18F\]APN-1607 uptake in subjects with MDAD, subjects with AD dementia, and...

Active, not recruiting
Alzheimer's Disease
Mild Cognitive Impairment Due to Alzheimer's Disease
Drug: [18F]APN-1607

Phase 2

APRINOIA Therapeutics

New Haven, Connecticut, United States and 2 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems